VIP is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Activates VPAC1 and VPAC2 class B G protein-coupled receptors, initiating adenylyl cyclase-cAMP cascade and CREB phosphorylation. Drives smooth muscle relaxation via calcium channel modulation, vasodilation through nitric oxide and prostacyclin production, neuroprotection via anti-inflammatory IL-10 induction, and enhanced insulin secretion via VPAC2 signaling.
How Does VIP Work in the Body?
VIP (Vasoactive Intestinal Peptide) is a Neuropeptide, vasodilator, anti-inflammatory. Endogenous 28-amino acid neuropeptide produced in gut, pancreas, brain, and neuroendocrine tissues.
Understanding its mechanism of action helps researchers design protocols and predict outcomes.
What Is the Primary Mechanism of VIP?
Activates VPAC1 and VPAC2 class B G protein-coupled receptors, initiating adenylyl cyclase-cAMP cascade and CREB phosphorylation. Drives smooth muscle relaxation via calcium channel modulation, vasodilation through nitric oxide and prostacyclin production, neuroprotection via anti-inflammatory IL-10 induction, and enhanced insulin secretion via VPAC2 signaling.
This mechanism operates at the cellular level and influences downstream pathways that produce the observable effects researchers study.
What Biological Pathways Does VIP Affect?
As a Neuropeptide, vasodilator, anti-inflammatory, VIP interacts with specific receptors and signaling cascades. These pathways are responsible for the compound's effects on vasodilation, bronchodilation, anti-inflammatory effects, neuroprotection, lung function improvement.
The multi-pathway activity is what gives VIP its broad potential application range — each pathway contributes to different aspects of the overall effect profile.
How Quickly Does VIP's Mechanism Take Effect?
With a half-life of 2 minutes (extremely short), VIP begins interacting with its target receptors within minutes of administration. However, the downstream biological effects take longer to manifest — typically days to weeks depending on the application.
Standard cycles run ongoing continuous therapy because that's the timeframe needed for the mechanism to produce measurable, cumulative results.
What Does the Research Say?
Phase 3 TESICO trial (471 patients with COVID-19) halted for futility with IV dosing. Phase 2 RCT (80 subjects, inhaled) showed positive signal. Orphan drug designation for pulmonary hypertension. Limited human data; research ongoing.
The only peptide addressing vasodilation, bronchoprotection, AND neuroprotection through a single receptor family — but its 2-minute half-life makes practical delivery the primary challenge.
Bottom Line on VIP's Mechanism
VIP works through neuropeptide, vasodilator, anti-inflammatory activity to influence vasodilation, bronchodilation, anti-inflammatory effects, neuroprotection, lung function improvement. Its mechanism involves multiple pathways, which is why it shows potential across several research applications.
See our VIP benefits guide for how this mechanism translates to practical outcomes.
Complete Guide
VIP : Benefits, Dosage, Side Effects & Research
Related Reading
Calculate Your VIP Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for VIP.
Open Calculator →Research-Grade Sourcing
If you're going to research VIP, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is VIP?
VIP (Vasoactive Intestinal Peptide) is a Neuropeptide, vasodilator, anti-inflammatory. Endogenous 28-amino acid neuropeptide produced in gut, pancreas, brain, and neuroendocrine tissues. It is researched for vasodilation, bronchodilation, anti-inflammatory effects, neuroprotection, lung function improvement.
What is the recommended VIP dosage?
Common dosages: 50-100 mcg per spray or 200 mcg daily inhaled administered 4 times daily (nasal) or daily (inhaled) via intranasal spray or inhalation. Cycle length: ongoing continuous therapy. Half-life: 2 minutes (extremely short). Use our peptide calculator for exact reconstitution math.
What are the side effects of VIP?
Limited clinical data. Nasal irritation possible. Short half-life limits systemic toxicity. Well-tolerated in preliminary studies.
Is VIP safe?
VIP has shown a favorable safety profile in research. Not FDA-approved. Orphan drug designation for pulmonary hypertension. FDA announced plans to remove from compounding lists. All research should follow appropriate safety protocols.